BioCentury | Nov 28, 2018
Preclinical News

Placental organoid could improve preeclampsia therapies

...outside of humans, so animal models of disease are limited in their predictive value (see "A1M...
BioCentury | Aug 14, 2018
Company News

Management tracks: Cheng departing Gilead as CMO

...and CMO Burkhard Blank will assume responsibility for manufacturing and technical operations. A1M Pharma AB (SSE:A1M...
BioCentury | Jun 23, 2016
Tools & Techniques

Home is in the placenta

...Lund University , to deliver recombinant A1M to the placenta. A1M Pharma has the recombinant A1M...
...will identify some that could provide new IP. Companies and Institutions Mentioned A1M Pharma AB (AktieTorget:A1M...
...digitalis-like factor (EDLF) in preeclampsia Phase II A1M Pharma AB (AktieTorget:A1M) A1M Recombinant α-1 microglobulin (A1M...
BioCentury | Apr 21, 2016
Product R&D

A1M for preeclampsia

...lead investigator A1M Pharma AB (AktieTorget:A1M), Lund University; Bo Åkerström, Stefan Hansson Figures Placental protection A1M...
...Stefan Hansson Figures Placental protection A1M Pharma AB (AktieTorget:A1M) is developing a recombinant form of A1M...
...stress. A1M Pharma's recombinant A1M can enhance the natural defense provided by the endogenous protein. A1M...
BioCentury | Mar 31, 2014
Company News

A1M Pharma, NeuroVive deal

...reached for details. A1M develops diagnostics and treatments for pre-eclampsia. The treatments are based on alpha-1 microglobulin (A1M)...
...NeuroSTAT has Orphan Drug designation in the U.S. and EU for TBI. A1M Pharma AB (AktieTorget:A1M...
BioCentury | Mar 28, 2011
Clinical News

PRO051: Additional Extension study data

...adverse events were irritation at the injection site, mild and variable proteinuria, and increased urinary alpha-1 microglobulin (A1M)...
Items per page:
1 - 6 of 6